Finerenone is recommended for patients with T2DM, an eGFR 25 mL/min/1.73 m2, normal serum potassium, and urinary albumin-to-creatinine ratio >30 mg/dL in addition to an ACE inhibitor an ARB at the maximum tolerated dose [130] or for persistent albuminuria in addition to a renin-angiotensin system inhibitor and SGLT2-i or in people with T2DM and CKD who cannot take an SGLT2-i [148]. The gene discussed is SLC5A2; the disease is chronic kidney disease.